Strides Pharma Science Acquires Sandoz's Portfolio, Set to Become Top Five Pharma Player in Sub-Saharan Africa
Strides Pharma Science Ltd.'s step-down subsidiary, Strides Pharma International AG, has entered into definitive agreements with Sandoz AG and its group entities for the acquisition and in-licensing of a portfolio of branded generic products across Sub-Saharan Africa. The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. The initial consideration for the transaction is US$ 12 million, payable at closing and is expected to be funded through internal accruals. The transaction is expected to close by the end of Q2 FY27, subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.
Key Highlights
- Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the represented market.
- The acquisition includes a portfolio of branded generic products across Sub-Saharan Africa, spanning four key markets—Western Sahara, Ghana, Nigeria, and Kenya.
- The transaction is expected to be EPS-accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage.
- The acquisition more than doubles Strides' presence in the region, giving the company the size and scale to accelerate its momentum, deepen market penetration, and further consolidate its leadership across key therapeutic areas.
- The transaction is expected to close by the end of Q2 FY27, subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.